Capricor Therapeutics (CAPR) 주식 개요
임상 단계의 생명공학 회사인 Capricor Therapeutics는 미국에서 듀센 근이영양증(DMD) 및 기타 미충족 의료 수요가 있는 질병을 치료하기 위한 형질 전환 세포 및 엑소좀 기반 치료제를 개발하는 회사입니다. 자세히 보기
CAPR Community Fair Values
Create NarrativeSee what 42 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Capricor Therapeutics, Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$21.51 |
| 52주 최고가 | US$40.37 |
| 52주 최저가 | US$4.30 |
| 베타 | 0.42 |
| 1개월 변동 | -15.08% |
| 3개월 변동 | -31.06% |
| 1년 변동 | 181.54% |
| 3년 변동 | 380.13% |
| 5년 변동 | 396.77% |
| IPO 이후 변동 | -48.79% |
최근 뉴스 및 업데이트
Recent updates
내러티브 업데이트 • Jun 15
CAPR: August FDA Decision On Duchenne Therapy Will Drive Long Term Upside Potential
Capricor Therapeutics' analyst price target has been cut by $5, to $38 from $43, as analysts factor in the removal of an expected $80 million milestone payment linked to the NS Pharma dispute and a later modeled U.S. launch for Deramiocel. Analyst Commentary Bullish analysts are recalibrating their models around the NS Pharma dispute and timing of the Deramiocel U.S. launch, yet some still see meaningful potential tied to upcoming regulatory and monetization events.Seeking Alpha • Jun 03
Capricor: I Rate It A Buy After Stress-Testing The Sell Thesis
Summary Capricor is rated a speculative Buy ahead of its August 22 PDUFA for deramiocel in Duchenne muscular dystrophy. Recent HOPE-3 data disclosures address most prior concerns about primary and cardiac endpoints, reducing trial-related risks. Key remaining risks include commercial disputes with NS Pharma/Nippon Shinyaku and limited initial manufacturing capacity. Valuation is not aggressive given a $600k net annual price and 2,500 US peak patients, but downside remains if the FDA issues a CRL or narrows the label. Read the full article on Seeking Alpha
내러티브 업데이트 • Jun 01
CAPR: FDA Decision And HOPE-3 Data Will Drive Bullish Repricing
Analysts have trimmed their average price target on Capricor Therapeutics by about $1.60 to roughly $39.40. This reflects adjustments for the removed $80m milestone and a later modeled Deramiocel U.S. launch, while still factoring in upcoming FDA decisions and related catalysts.내러티브 업데이트 • May 15
CAPR: August PDUFA Decision Will Shape Duchenne Treatment Adoption Outlook
Narrative Update: Capricor Therapeutics Analyst Price Target Shift The analyst price target for Capricor Therapeutics has been reduced by $5 to $38, as analysts factor in the removal of an expected $80 million milestone payment and a later modeled U.S. launch for Deramiocel following the company’s legal action against NS Pharma. Analyst Commentary Recent Street research around Capricor Therapeutics has shifted from purely optimistic toward a more balanced stance, as bullish analysts factor in both regulatory progress for Deramiocel and the impact of the company’s legal action against NS Pharma.
내러티브 업데이트 • Apr 29
CAPR: August PDUFA Cardiac Data Will Drive Bullish 2026 Approval Setup
Narrative Update: Capricor Therapeutics The updated analyst price target framework for Capricor Therapeutics moves from a prior fair value of $50.80 to $54.67. This reflects analysts' use of higher projected revenue growth, wider profit margins and a higher future P/E multiple following recent positive deramiocel data, FDA review progress and a series of target increases across the Street.내러티브 업데이트 • Apr 15
CAPR: August PDUFA Decision Will Drive Bullish Duchenne Thesis
Analysts have lifted their average price targets on Capricor Therapeutics into a $41 to $63 range, supported by recent FDA progress on deramiocel for Duchenne muscular dystrophy, additional positive Phase 3 HOPE-3 data, and updated cash and review timelines that feed into modest tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions in the valuation model. Analyst Commentary Bullish analysts are largely framing recent volatility in Capricor Therapeutics as a short-term shakeout rather than a shift in the long-term story.내러티브 업데이트 • Apr 01
CAPR: August PDUFA And HOPE 3 Readout Will Shape Bullish Case
Analysts have lifted their blended price target on Capricor Therapeutics to $63, supported by higher targets from several firms. These firms point to recent FDA milestones for deramiocel in Duchenne muscular dystrophy, additional Phase 3 HOPE-3 data, and updated PDUFA timing as key drivers behind their refreshed assumptions.내러티브 업데이트 • Mar 18
CAPR: August PDUFA Decision And HOPE 3 Data Will Drive Bullish Outlook
Narrative Update on Capricor Therapeutics The analyst fair value estimate for Capricor Therapeutics has moved from $62.00 to $63.00, reflecting updated Street research that points to higher price targets tied to recent FDA progress for deramiocel in Duchenne muscular dystrophy and supportive Phase 3 HOPE-3 data. Analyst Commentary Recent Street research has been broadly constructive on Capricor Therapeutics, with bullish analysts highlighting regulatory milestones for deramiocel in Duchenne muscular dystrophy and updated Phase 3 HOPE-3 data as key drivers behind their views.내러티브 업데이트 • Mar 03
CAPR: HOPE 3 Data And BLA Resubmission Will Drive Bullish 2026 Approval Path
Analysts now place a slightly higher implied value on Capricor Therapeutics, with their updated price target moving to $62.00. This is supported by modest tweaks to the discount rate, revenue growth assumptions, and long-term profit margin and P/E inputs.내러티브 업데이트 • Feb 17
CAPR: HOPE-3 Regulatory Progress And Capital Raise Will Drive Bullish Repricing
Analysts have kept their $41.00 price target for Capricor Therapeutics unchanged, citing only minor model adjustments such as slightly different discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Capricor provided a regulatory update on its Biologics License Application for Deramiocel in Duchenne muscular dystrophy, with the FDA requesting the full Phase 3 HOPE-3 clinical study report and supporting data to address a Complete Response Letter, without asking for additional clinical studies or new patient data.내러티브 업데이트 • Feb 03
CAPR: Phase 3 Duchenne Cardiac Results Will Shape Bullish 2026 Approval Path
Narrative Update The analyst price target for Capricor Therapeutics has moved from about US$44.56 to US$50.80, with analysts pointing to expectations around Phase 3 HOPE-3 data for Deramiocel in Duchenne muscular dystrophy cardiomyopathy and updated modeling assumptions as key drivers of the change. Analyst Commentary Recent Street research points to a change in how some analysts are framing risk and potential reward around Capricor Therapeutics, especially with Phase 3 HOPE-3 data for Deramiocel in Duchenne muscular dystrophy cardiomyopathy expected in Q4.내러티브 업데이트 • Jan 20
CAPR: HOPE 3 Cardiac Outcome Data Will Shape Bullish Mid 2026 Approval Path
The analyst price target for Capricor Therapeutics has increased from $12 to $13, as analysts incorporate updated assumptions for Deramiocel approval in Duchenne muscular dystrophy cardiomyopathy and anticipated Phase 3 HOPE-3 cardiac outcome data. Analyst Commentary Bullish analysts are framing the price target move to US$13 as a reflection of updated expectations around Deramiocel in Duchenne muscular dystrophy cardiomyopathy rather than a broad shift in the overall story.내러티브 업데이트 • Jan 06
CAPR: HOPE-3 Duchenne Cardiac Data Will Drive Bullish Repricing
Analysts have lifted their fair value estimate for Capricor Therapeutics from $12.00 to $41.00 per share, citing updated assumptions around Deramiocel approval prospects in Duchenne muscular dystrophy cardiomyopathy, following recent Street research and price target revisions. Analyst Commentary Recent Street commentary around Capricor Therapeutics has centered on expectations for Deramiocel in Duchenne muscular dystrophy cardiomyopathy, with valuation work closely tied to regulatory outcomes and clinical readouts for the Phase 3 HOPE-3 trial anticipated in Q4.내러티브 업데이트 • Dec 19
CAPR: Mid 2026 Approval Path Will Drive HOPE 3 Cardiac Catalyst Narrative
Analysts have sharply increased their price target for Capricor Therapeutics, effectively more than doubling fair value from approximately $29 to about $62. They cite higher projected revenue growth, a dramatic improvement in long term profit margins, a more normalized future earnings multiple, and growing confidence that positive HOPE-3 data could support regulatory flexibility and keep a potential Deramiocel approval on track for mid 2026.내러티브 업데이트 • Dec 05
CAPR: Phase 3 Duchenne Cardiac Data Will Drive 2026 Approval Hopes
Analysts have sharply raised their price target on Capricor Therapeutics, with the modeled fair value estimate climbing from about $20.60 to roughly $44.56 per share. They cite stronger expected revenue growth, significantly improved profit margins, and increasing confidence that positive HOPE-3 Phase 3 data could support Deramiocel approval for Duchenne muscular dystrophy cardiomyopathy on an accelerated mid 2026 timeline.분석 기사 • Nov 05
We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...분석 기사 • Sep 09
Capricor Therapeutics, Inc. (NASDAQ:CAPR) May Have Run Too Fast Too Soon With Recent 30% Price Plummet
To the annoyance of some shareholders, Capricor Therapeutics, Inc. ( NASDAQ:CAPR ) shares are down a considerable 30...분석 기사 • Jun 24
Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
To the annoyance of some shareholders, Capricor Therapeutics, Inc. ( NASDAQ:CAPR ) shares are down a considerable 25...분석 기사 • May 16
Here's Why We Think Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO Compensation Looks Fair
Key Insights Capricor Therapeutics to hold its Annual General Meeting on 22nd of May CEO Linda Marbán's total...분석 기사 • May 09
Capricor Therapeutics, Inc. (NASDAQ:CAPR) May Have Run Too Fast Too Soon With Recent 26% Price Plummet
Unfortunately for some shareholders, the Capricor Therapeutics, Inc. ( NASDAQ:CAPR ) share price has dived 26% in the...
새로운 내러티브 • May 03
FDA Priority Review And NS Pharma Partnership Will Empower Deramiocel
FDA priority review of deramiocel and partnership with NS Pharma could drive significant revenue growth and market penetration.분석 기사 • Mar 29
New Forecasts: Here's What Analysts Think The Future Holds For Capricor Therapeutics, Inc. (NASDAQ:CAPR)
Capricor Therapeutics, Inc. ( NASDAQ:CAPR ) shareholders will have a reason to smile today, with the analysts making...분석 기사 • Mar 19
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely
Capricor Therapeutics, Inc. ( NASDAQ:CAPR ) shareholders won't be pleased to see that the share price has had a very...분석 기사 • Dec 12
Some Capricor Therapeutics, Inc. (NASDAQ:CAPR) Shareholders Look For Exit As Shares Take 27% Pounding
The Capricor Therapeutics, Inc. ( NASDAQ:CAPR ) share price has softened a substantial 27% over the previous 30 days...Seeking Alpha • Dec 06
Capricor: Additional Deramiocel Data Bodes Well For Initiated Rolling BLA Submission
Summary Capricor Therapeutics initiated its rolling BLA submission for Deramiocel to treat Duchenne Muscular Dystrophy Cardiomyopathy, with completion expected before the end of 2024. The company presented promising 3-year data from the HOPE-2 OLE study, showing significant improvements in cardiac and skeletal muscle functions. Capricor raised $86.3 million in a public offering, ensuring sufficient cash runway to fund operations into 2027, excluding potential milestone payments from Nippon Shinyaku. The global Duchenne Muscular Dystrophy treatment market is expected to reach $8.19 billion by 2029. Read the full article on Seeking Alpha주주 수익률
| CAPR | US Biotechs | US 시장 | |
|---|---|---|---|
| 7D | -7.3% | -2.4% | 0.7% |
| 1Y | 181.5% | 35.9% | 20.6% |
수익률 대 산업: CAPR은 지난 1년 동안 35.9%의 수익을 기록한 US Biotechs 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: CAPR은 지난 1년 동안 20.6%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| CAPR volatility | |
|---|---|
| CAPR Average Weekly Movement | 9.6% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
안정적인 주가: CAPR는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: CAPR의 주간 변동성은 지난 1년간 54%에서 10%로 감소했습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2005 | 231 | Linda Marbán | www.capricor.com |
임상 단계의 생명공학 회사인 Capricor Therapeutics는 미국에서 듀센 근이영양증(DMD) 및 기타 미충족 의료 수요가 있는 질병을 치료하기 위한 형질 전환 세포 및 엑소좀 기반 치료제를 개발하는 회사입니다. 주요 제품 후보로는 동종 심근 유래 세포인 데라미오셀이 있으며, DMD 치료를 위한 임상 3상 시험이 진행 중입니다. 또한 엑소좀 단백질 기반 백신을 개발하여 SARS-CoV-2 치료를 위한 전임상 시험을 진행 중이며, 백신 및 치료제 개발을 위한 엔지니어드 엑소좀으로 구성된 엑소좀 플랫폼 프로그램인 StealthX 엑소좀 플랫폼을 개발하여 전임상 시험을 진행 중입니다.
Capricor Therapeutics, Inc. 기초 지표 요약
| CAPR 기초 통계 | |
|---|---|
| 시가총액 | US$1.30b |
| 순이익 (TTM) | -US$114.59m |
| 매출 (TTM) | n/a |
0.0x
주가매출비율(P/S)-10.9x
주가수익비율(P/E)CAPR는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| CAPR 손익계산서 (TTM) | |
|---|---|
| 매출 | US$0 |
| 매출원가 | US$92.92m |
| 총이익 | -US$92.92m |
| 기타 비용 | US$21.68m |
| 순이익 | -US$114.59m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | -1.98 |
| 총이익률 | 0.00% |
| 순이익률 | 0.00% |
| 부채/자본 비율 | 0% |
CAPR의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/07/10 16:20 |
| 종가 | 2026/07/10 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Capricor Therapeutics, Inc.는 9명의 분석가가 다루고 있습니다. 이 중 10명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Matthew Venezia | Alliance Global Partners |
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Kristen Kluska | Cantor Fitzgerald & Co. |